In contrast, they also showed the downmodulation of NCR (Nkp30 and NKp46) and NKG2D in NK-92 cells and NK cells of healthy donors treated with the supernatant of HeLa, SiHa, and C-33A cervical cancer cells and how the pre-treatment with the HO-1 inhibitor restored the expression of NKG2D and NKp30. This evidence concerns the gene NCR3 and cervical carcinoma.